Search Site
Home >> Signaling Pathways >> Apoptosis >> Caspase >> Z-VAD-FMK
Related Biochemicals Related Antibodies


Cell-permeable, irreversible pan-caspase inhibitor


Catalog No. A1902
Size Price Stock Qty
Evaluation Sample $28.00  All Inclusive In stock
1mg $55.00 In stock
5mg $150.00 In stock
10mg $250.00 In stock
25mg $400.00 In stock

All inclusive: Shipping and all other fees included

Tel: +1-832-696-8203


Worldwide Distributors

Sample solution is provided at 25 µL, 10mM.

Product Citations

1. Boyd-Tressler, Andrea, et al. "Chemotherapeutic Drugs Induce ATP Release via Caspase-gated Pannexin-1 Channels and a Caspase/Pannexin-1-Independent Mechanism." Journal of Biological Chemistry (2014): jbc-M114. PMID:25112874

Quality Control

Related Biological Data

zVAD was able to completely suppress the proteolytic processing of Panx1 at each incubation time point in the anti-Fas treated Jurkat cells [1].
1. Boyd-Tressler A, Penuela S, Laird D W, et al. Chemotherapeutic Drugs Induce ATP Release via Caspase-gated Pannexin-1 Channels and a Caspase/Pannexin-1-Independent Mechanism. Journal of Biological Chemistry, 2014: jbc. M114. 590240.

Related Biological Data


Related Biological Data


Related Biological Data

Apoptosis was induced by Paclitaxel and the cells were then treated with Z-VAD-FMK and Q-VD-OPH at 0,10,20, and 50um. Caspase activities were measured by Promega Caspase-Glo assay were compared with vehicle control.

Biological Activity

Cell-permeable, irreversible pan-caspase inhibitor. Inhibits caspase processing and apoptosis induction in tumor cells in vitro (IC50 = 0.0015 - 5.8 mM). Active in vivo.
Targets Caspase          
IC50 0.0015 - 5.8 mM          


Kinase experiment [1]:

Preventing the processing of CPP32 to its active form

Z-VAD.FMK inhibits apoptosis by inhibiting the activation of CPP32, which presumably blocked the process  by interfering directly with the processing of CPP32.

Kinase experiment [1]:

Cell lines

Human CD4+ (~ 97%) and CD8+ T (~ 98%) cells 

Preparation method

This product is soluble in DMSO mostly at 198 mM. It is also soluble in water with no more than 1 mM. Stock solution can be stored at -80 ℃ less than 6 months.

Reacting time

24 h


z-VAD-FMK dose-dependently inhibited T cell proliferation mediated through the co-stimulation with anti-CD3 and anti-CD28. z-IETD-FMK was less effective at 25 and 50 μM, but inhibited T cell proliferation at the 100 μM concentration.

Z-VAD-FMK Dilution Calculator

Concentration (start)
Volume (start)
Concentration (final)
Volume (final)


Z-VAD-FMK Molarity Calculator



Chemical Properties

Cas No. 187389-52-2 SDF Download SDF
Synonyms Benzyloxycarbonyl-Val-Ala-Asp(OMe)-fluoromethylketone,Z-Val-Ala-Asp(OMe)-FMK
Chemical Name methyl (3S)-5-fluoro-3-[[(2S)-2-[[(2S)-3-methyl-2-(phenylmethoxycarbonylamino)butanoyl]amino]propanoyl]amino]-4-oxopentanoate
Formula C22H30FN3O7 M.Wt 467.49
Solubility Soluble in DMSO Storage Store at -20°C
Shipping Condition: Evaluation sample solution : ship with blue ice
All other available size: ship with RT , or blue ice upon request

View Related Products By Research Topics

Research Update

1. Suppression of human T cell proliferation by the caspase inhibitors, z-VAD-FMK and z-IETD-FMK is independent of their caspase inhibition properties. Toxicol Appl Pharmacol. 2012 Nov 15;265(1):103-12. doi: 10.1016/j.taap.2012.09.002. Epub 2012 Sep 12.
The caspase inhibitor Z-VAD-FMK exhibits immunosuppressive and anti-proliferative activities in T cell without inhibiting the activity of caspases 8 and 3, where it inhibits NF-KB, the expression of CD25 and FasL-induced apoptosis.
2. [Inhibition of elicitation of allergic contact dermatitis by topical use of Z-VAD-FMK, a broad caspase inhibitor: experiment in mice]. Zhonghua Yi Xue Za Zhi. 2012 Jul 24;92(28):1992-6.
The effects of Z-VAD-FMK, a caspase inhibitor, on T lymphocytes and the elicitation of murine ACD were investigated.
3. Radiation-induced cytochrome c release and the neuroprotective effects of the pan-caspase inhibitor z-VAD-fmk in the hypoglossal nucleus. Exp Ther Med. 2014 Feb;7(2):383-388. Epub 2013 Nov 20.
Intracerebroventricular administration of Z-VAD-FMK, a caspase inhibitor restricted by blood-brain barrier, to post-radiation rats resulted in reduced numbers of TUNEL-positive cells in the hypoglossal nucleus, suppressed expression and activation of caspases 3/8/9 and decrease appearance of cytochrome c in the cytosolic fraction.
5. Intracochlear perfusion of leupeptin and z-VAD-FMK: influence of antiapoptotic agents on gunshot-induced hearing loss. Eur Arch Otorhinolaryngol. 2011 Jul;268(7):987-93. doi: 10.1007/s00405-011-1487-0. Epub 2011 Jan 19.
Early direct infusion of Z-VAD-FMK, a caspase inhibitor, into cochlear leads to accelerated hearing recovery and reduced hair cell loss in pigs suffering gunshot noise-induced trauma.


Z-VAD-FMK, an inhibitor of ICE-like proteases, inhibits apoptosis in THP.1 cells induced by diverse stimuli1 and Fas antigen-induced apoptosis in Jurkat T-cells2. It inhibits apoptosis by blocking the activation of proCPP32 into its active form, rather than by preventing the proteolytic action of CPP32 directly.

Z- VAD-FMK inhibits the formation of large kilobasepair fragments of DNA induced by diverse stimuli. Z-VAD-FMK had little or no effect on STS-induced necrotic cell death suggesting that the ICE-like protease activity was not involved in necrosis3.

Z-VAD-FMK almost completely inhibited the formation of large kilobasepair induced by all four stimuli. Similarly Z-VAD-FMK almost completely inhibited the enhanced formation of large kilobasepair fragments induced by thapsigargin or cycloheximide in the presence of TLCK, in good agreement with its ability to inhibit apoptosis induced by these treatments. These stimuli also induced internucleosomal cleavage of DNA, which was inhibited by Z-VAD-FMK. These results suggested that an ICE-like protease(s) acts at a stage prior to the formation of large kilobasepair fragments of DNA3.

1. Darmon, A.J., Ehrman, N., Caputo, A., Fujinaga, J. and Bleackley, R.C. (1994) J. Biol. Chem. 269, 32043-32046.
2. Chow, S. C., Weis M., Kass, G. E. N., Holmstrom, T. H., Eriksson, J. E. and Orrenius S. (1995) FEBS Lett. 364, 134±138
3. H. Zhu et al./FEBS Letters 374 (1995) 303-308